Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05990127 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Name: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer — clinical trial record (NCT05990127)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorAkeso

Started2023-11-14

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 14, 2023 (before its estimated August 5, 2025 completion). Its status may not reflect the trial's current state.

Akeso

96 trials monitored

See 1 trial at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS \< 1%.

Trial Details

NCT Number	NCT05990127
Lead Sponsor	Akeso
Conditions	Locally Advanced or Metastatic NSCLC
Enrollment	642 participants
Start Date	2023-11-14
Primary Completion	2025-08-05 (estimated)
Study Completion	2026-11-28 (estimated)
Updated on ClinicalTrials.gov	2023-08-14